Fulltext

Repeated injections of 131I-rituximab show patient-specific stable biodistribution and tissue kinetics

Antonescu, Cristian ; Bischof Delaloye, Angelika ; Kosinski, Marek ; Monnin, Pascal ; Schaffland, Andreas ; Ketterer, Nicolas ; Grannavel, Carine ; Kovacsovics, Tibor ; Verdun, Francis ; Buchegger, Franz

In: European Journal of Nuclear Medicine and Molecular Imaging, 2005, vol. 32, no. 8, p. 943-951

Ajouter à la liste personnelle
    Titre
    • Repeated injections of 131I-rituximab show patient-specific stable biodistribution and tissue kinetics
    Auteur
    • Antonescu, Cristian. Service of Nuclear Medicine, University Hospital of Lausanne, Rue du Bugnon 46, 1011, Lausanne, Switzerland
    • Bischof Delaloye, Angelika. Service of Nuclear Medicine, University Hospital of Lausanne, Rue du Bugnon 46, 1011, Lausanne, Switzerland
    • Kosinski, Marek. Service of Nuclear Medicine, University Hospital of Lausanne, Rue du Bugnon 46, 1011, Lausanne, Switzerland
    • Monnin, Pascal. Institute of Applied Radiophysics, University of Lausanne, Lausanne, Switzerland
    • Schaffland, Andreas. Service of Nuclear Medicine, University Hospital of Lausanne, Rue du Bugnon 46, 1011, Lausanne, Switzerland
    • Ketterer, Nicolas. Multidisciplinary Oncology Center, University Hospital of Lausanne, Lausanne, Switzerland
    • Grannavel, Carine. Service of Nuclear Medicine, University Hospital of Lausanne, Rue du Bugnon 46, 1011, Lausanne, Switzerland
    • Kovacsovics, Tibor. Center for Hematological Malignancies, Oregon Health and Science University, Portland, OR, USA
    • Verdun, Francis. Institute of Applied Radiophysics, University of Lausanne, Lausanne, Switzerland
    • Buchegger, Franz. Service of Nuclear Medicine, University Hospital of Lausanne, Rue du Bugnon 46, 1011, Lausanne, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • European Journal of Nuclear Medicine and Molecular Imaging, 2005, vol. 32, no. 8, p. 943-951. Springer-Verlag; http://www.springer.de
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:320172
    Summary
    Purpose: It is generally assumed that the biodistribution and pharmacokinetics of radiolabelled antibodies remain similar between dosimetric and therapeutic injections in radioimmunotherapy. However, circulation half-lives of unlabelled rituximab have been reported to increase progressively after the weekly injections of standard therapy doses. The aim of this study was to evaluate the evolution of the pharmacokinetics of repeated 131I-rituximab injections during treatment with unlabelled rituximab in patients with non-Hodgkin's lymphoma (NHL). Methods: Patients received standard weekly therapy with rituximab (375mg/m2) for 4 weeks and a fifth injection at 7 or 8 weeks. Each patient had three additional injections of 185MBq 131I-rituximab in either treatment weeks 1, 3 and 7 (two patients) or weeks 2, 4 and 8 (two patients). The 12 radiolabelled antibody injections were followed by three whole-body (WB) scintigraphic studies during 1 week and blood sampling on the same occasions. Additional WB scans were performed after 2 and 4 weeks post 131I-rituximab injection prior to the second and third injections, respectively. Results: A single exponential radioactivity decrease for WB, liver, spleen, kidneys and heart was observed. Biodistribution and half-lives were patient specific, and without significant change after the second or third injection compared with the first one. Blood T1/2β, calculated from the sequential blood samples and fitted to a bi-exponential curve, was similar to the T1/2 of heart and liver but shorter than that of WB and kidneys. Effective radiation dose calculated from attenuation-corrected WB scans and blood using Mirdose3.1 was 0.53+0.05mSv/MBq (range 0.48-0.59mSv/MBq). Radiation dose was highest for spleen and kidneys, followed by heart and liver. Conclusion: These results show that the biodistribution and tissue kinetics of 131I-rituximab, while specific to each patient, remained constant during unlabelled antibody therapy. RIT radiation doses can therefore be reliably extrapolated from a preceding dosimetry study